Drug Profile
VM 1501
Alternative Names: VM1501Latest Information Update: 03 Oct 2023
Price :
$50
*
At a glance
- Originator Viriom
- Class Antivirals
- Mechanism of Action Non-nucleoside reverse transcriptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 03 Oct 2023 Discontinued - Preclinical for HIV infections in Russia (PO)
- 28 Aug 2019 No recent reports of development identified for preclinical development in HIV-infections in Russia (PO)
- 02 Jul 2019 Viriom enters into a licensing agreement with Lloyds Pharma for elsulfavirine and other drugs from Viriom HIV and Hepatitis B portfolio in Indonesia